Waander L. van Heerde

CEO
Enzyre BV

Presentation(s):

• PB1184 - Dose-effect analyses of FEIBA in low volume plasma samples of inhibitor patients using a newly defined chemiluminescent-based TGA

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1185 - Novel miniaturized Chemiluminescent-based Factor VIII activity assay

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• PB1186 - A novel chemiluminescent-based Thrombin Generation Assay for near-patient monitoring.

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM